ReviewBritish journal of clinical pharmacology2018
Low molecular weight heparin for the prevention of severe preeclampsia: where next?
Review in British journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 32 citations in OpenAlex.
- The Immunopathology of Preeclampsia.Biomedicines · 2026Review
- Evidence that atherosis of the spiral artery represents atherosclerotic lesions similar to those of native and transplant-induced atherosclerosis: implications for understanding the pathophysiology of obstetrical syndromes and long-term cardiovascular risk.American journal of obstetrics and gynecology · 2025Article
- Kidney health outcomes of hypertensive disorders of pregnancy.Nature reviews. Nephrology · 2025Review
- Secondary prevention of preeclampsia.Frontiers in cell and developmental biology · 2025Review
- LMWH prevents thromboinflammation in the placenta via HBEGF-AKT signaling.Blood advances · 2024Article
- Perturbations in kinetics of the thrombin generation assay identify women at risk of preeclampsia in the first trimester and provide the rationale for a preventive approach.American journal of obstetrics and gynecology · 2023Article
- Alternative pathway activation in pregnancy, a measured amount "complements" a successful pregnancy, too much results in adverse events.Immunological reviews · 2023Review
- FIGO (international Federation of Gynecology and obstetrics) initiative on fetal growth: best practice advice for screening, diagnosis, and management of fetal growth restriction.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2021Article
- Dysregulation of Complement Activation and Placental Dysfunction: A Potential Target to Treat Preeclampsia?Frontiers in immunology · 2019Review
- Effects of glycol-split low molecular weight heparin on placental, endothelial, and anti-inflammatory pathways relevant to preeclampsia.Biology of reproduction · 2018Article
- Low molecular weight heparin for the prevention of severe preeclampsia: where next?British journal of clinical pharmacology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low molecular weight heparin has been extensively evaluated for the prevention of preeclampsia in high-risk pregnant women; however, the results from these trials have been conflicting. This review discusses the potential mechanisms of action of low molecular weight heparin for the prevention of severe preeclampsia, how to optimize the selection of high-risk women for participation in future trials, and the importance of trial standardization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.